StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) stock

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)

Close on Nov 17, 2026Market cap $152.14MP/E –Yield –

Korsana Biosciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Korsana Biosciences's total debt was $3.50M at Dec 31, 2022. For fiscal 2022 it was $3.50M, up 0.0% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2022Dec 31, 2022$3.50M0.0%
FY2021Dec 31, 2021$3.50M0.0%
FY2020Dec 31, 2020$3.50M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$3.50M–
Q4 FY2021Dec 31, 2021$3.50M–
Q4 FY2020Dec 31, 2020$3.50M–
Q3 FY2020Sep 30, 2020$3.50M–

More Korsana Biosciences figures

See a number that looks wrong?